In re: Delhi-NCR Super-Speciality Hospitals (CCI, 2026): no Section 4 abuse without dominance in a correctly defined market

Excessive in-hospital prices are a familiar grievance — the room that costs more than a hotel, the syringe that carries a higher printed price than the chemist down the road, the lab test billed above a standalone diagnostic centre. The question this matter answered is whether those grievances, however real, translate into an abuse of dominance under competition law. The Competition Commission of India's answer, after a decade of investigation, was no — not because the prices were demonstrably fair, but because the legal precondition for the inquiry, dominance in a properly defined market, was absent.

The facts in brief

The matter began in 2015 with information filed by Vivek Sharma against Becton Dickinson India Pvt. Ltd. and Max Super Specialty Hospital, Patparganj. Sharma alleged that Becton Dickinson, in concert with the hospital, printed a higher maximum retail price (MRP) on disposable syringes sold through the hospital's in-house pharmacy than on the identical product sold in the open market. The Commission directed an investigation. The Director General (DG) found that the alleged collusion under Section 3 between Becton Dickinson and Max Patparganj was not substantiated, but the inquiry had by then widened into the larger question of "aftermarket" conduct — whether admitted patients, once inside a hospital, become captive consumers who can be overcharged for goods and services bundled into their treatment.

On that wider question the DG examined twelve super-speciality hospitals across Delhi-NCR, including several Max hospitals (Patparganj, Saket, Shalimar Bagh, BLK Max and others), Fortis (Vasant Kunj and Fortis Escorts Heart Institute), Sir Ganga Ram Hospital, Indraprastha Apollo, Batra Hospital and St Stephen's Hospital. The DG concluded that each hospital was dominant in its own relevant market for in-patient healthcare services, and that there had been contravention of Section 4 between 2015 and 2018 on five parameters: room rent, medical tests, medical devices, consumables and medicines.

The question

Could the twelve hospitals be said to abuse a dominant position under Section 4 by charging patients excessive or unfair prices for room rent, tests, devices, consumables and medicines? That question turns first on a logically prior one: what is the relevant market, and is any hospital dominant within it? Under the scheme of the Act, abuse of dominance is only actionable where dominance is first established; the unfairness of a price is assessed only after that threshold is crossed.

What the Commission held

The Commission, in May 2026, declined to follow the DG's conclusions and closed the proceedings. It held that the relevant market could not be narrowed to each individual hospital. Instead, the correct frame was the broader market for the provision of healthcare services by super-speciality hospitals in Delhi-NCR — a market in which no single hospital, on the material before the Commission, held a dominant position.

The Commission's reasoning rested on the integrated nature of hospital services. As reported, the Commission reasoned that patients do not approach hospitals to buy standalone goods such as medicines, consumables or medical devices; they come for treatment, of which those items form one part. Because the goods complained of were inputs to an integrated treatment service rather than separately demanded products, the DG's attempt to carve out per-item or per-hospital markets did not hold. On pricing, the Commission found that the two-stage test for excessive pricing was not satisfied. Procurement cost alone could not be the yardstick for unfairness, because it ignored overheads such as storage, logistics, inventory and operational expenses; and, the Commission added, selling medicines or consumables at MRP is not by itself illegal. It rejected the DG's benchmarks as ill-matched: hospital rooms could not be equated with hotel tariffs because they serve clinical rather than hospitality needs, and hospital laboratories could not be measured against standalone diagnostic centres because, among other things, hospital labs operate round the clock and may offer faster turnaround.

Analysis

The order is a disciplined restatement of the sequence Section 4 demands. Dominance is assessed under the factors in Section 19(4) within a relevant market; only once dominance is established does the question of abusive pricing under Section 4(2) arise. By collapsing the relevant market into each hospital, the DG had effectively guaranteed a finding of dominance — every provider is "dominant" in the market consisting of itself — and then proceeded to the pricing inquiry as though dominance were settled. The Commission's correction was to refuse that shortcut: define the market on demand-side substitutability across Delhi-NCR's super-speciality hospitals, and dominance evaporates.

The "aftermarket" theory deserves particular attention. The intuitive worry — that an admitted patient is a captive consumer who cannot shop around for a cheaper syringe — is precisely the concern that aftermarket abuse doctrine addresses in other settings. The Commission's response is that captivity at the point of consumption does not, without more, create a separate aftermarket where the goods are not independently demanded but are components of a single integrated service chosen ex ante. A patient selects a hospital for treatment; the medicines and consumables are not a distinct downstream market in which the patient is locked. That framing will be contested, and it sits alongside the Commission's contemporaneous treatment of similar arguments in the Max Super Specialty aftermarket discussion, but as applied here it disposed of the per-item market theory.

Equally important is what the Commission did not decide. It did not bless hospital pricing as fair, nor foreclose regulation of in-hospital charges through other instruments. It held only that, on this record and within competition law's framework, the conduct did not amount to abuse of a dominant position. The unfairness of a price is a Section 4 question only after dominance; absent dominance, the Commission has no occasion to police price levels, and price control is a matter for sectoral regulation rather than the Competition Act.

Why it matters

For hospital groups and their advisers, the order confirms that exposure under Section 4 begins and ends with market definition. A complaint that frames each hospital, or each in-hospital product, as its own market will struggle once the Commission applies a demand-side substitution analysis across the metropolitan region. For complainants, the lesson is that "captive consumer" rhetoric is not a substitute for proving dominance in a coherently defined market, and that procurement-cost-versus-MRP comparisons will not, on their own, establish unfair pricing. More broadly, the decision reaffirms a structural limit on the Commission's mandate: competition law is not a general price-fairness regulator, and grievances about high medical bills, however legitimate, may need to be addressed through sectoral price regulation rather than the abuse-of-dominance route.

Related on Valkya

• Amazon v. CCI: Section 45(2) is not a review power
• Excel Crop Care v. CCI: relevant turnover for penalty
• CCI v. Roppen (Rapido): the jurisdictional boundary
• Keshav Bihani v. CCI: polyacetal tubes cartel and Section 48

Sources

• CCI closes abuse of dominance case against 12 Delhi-NCR hospitals for overcharging patients — Bar & Bench
• Competition Commission of India — case record, Vivek Sharma v. Becton Dickinson India Pvt. Ltd. (Case No. 77 of 2015)